In order to save the world and benefit the people, Naodesheng Biotechnology Co., Ltd. was founded in 1999 as a life technology research and development-oriented company. Traditional Chinese medicines have the characteristics of mildness, safety and effectiveness. New medicines are researched and developed from a single plant or a compound of multiple Chinese medicines. After years of continuous hard research, the R&D department first developed the compound lead drug "BNG-1" for the treatment of stroke and cardiovascular disease.

       In order to confirm the pharmacological activity and effectiveness of BNG-1, the R&D team commissioned the Pan Global Institute of Pharmacology (MDS PANLABS) to conduct up to 88 "general animal pharmacological activity experiments" in 1987, and screened out that it can inhibit eicosenoic acid. Induces platelet aggregation reaction, and prolongs the clotting time, and has the effect of mildly strengthening the heart and enhancing atrial contractility. Afterwards, a stroke animal model experiment was conducted to confirm the preventive and therapeutic effects of BNG-1 against "prevention and treatment of cerebral artery occlusion". In vitro experiments on enzyme activity found that its mechanism of action is to inhibit the activity of phosphodiesterase (PDE), especially for phosphodiesterase type I (PDE1: Cerebral Vascular Smooth Muscle Relaxation) And the seventh type (PDE7A1: anti-inflammatory and neuroprotective) has an index of inhibitory effect. This experiment found to bring answers to the entire pharmacology, and also makes the pharmacological experiment of BNG-1 more complete.

 

        In addition, in terms of safety pharmacology evaluation, it also commissioned the Pan Global Pharmacology Institute to complete the large animal "safety pharmacological test", and commissioned the Consortium Biotechnology Research and Development Center (DCB) to complete the "toxicological safety test", all of which are safe The standard of non-toxicity meets the safety regulations of human clinical trials.

 

        Finally, a professional research institution was entrusted to conduct quality control of raw materials and manufacturing processes, and chemical analysis. Then, in accordance with the rigorous western medicine development model of the FDA, a group of neurologists from 19 domestic medical centers in accordance with the Good Clinical Trial Specifications of the Republic of China At the end of 2014, the third phase of the "randomized, double-blind, multi-center clinical study for the recovery of ischemic stroke, comparing the functional results and safety of the combined use of BNG-1 and Aspirin with the use of Aspirin alone" was completed by the Department of Health at the end of 2014. Human clinical trial case.

 

       BNG-1 Powder (BNG-1 Powder) has passed the New Drug Inspection Registration (NDA) review on September 11, 2020, and obtained the Drug License No. 060064 of the Ministry of Health and Welfare, making Hanfang Be scientific, modern and international, and be in line with the world, bring more benefits to the public, and will have a multiplier effect and contribution to the development of domestic biotechnology and pharmaceutical industry technology. "BNG-1" is expected to be in 2021 Officially listed in the first quarter.